A 54-year-old woman with HIV has been taking dolutegravir plus tenofovir alafenamide-emtricitabine for about 2 years. She had suppressed HIV RNA levels, and she has maintained suppressed HIV RNA levels since then. A baseline HIV drug resistance genotype showed an M184V mutation but no other mutations. In the past 3 months, she has developed some esophageal problems and is having extreme difficulty swallowing pills. She is very interested in taking long-acting injectable cabotegravir and rilpivirine injections instead of daily pills.